Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy, Safety, and Tolerability of BLU-5937 for the Treatment of Chronic Pruritus in Adult Subjects With Atopic Dermatitis

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy, Safety, and Tolerability of BLU-5937 for the Treatment of Chronic Pruritus in Adult Subjects With Atopic Dermatitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camlipixant (Primary)
  • Indications Atopic dermatitis; Pruritus
  • Focus Proof of concept; Therapeutic Use
  • Acronyms BLUEPRINT
  • Sponsors BELLUS Health

    • Most Recent Events

    • 13 Dec 2021 According to a BELLUS Health media release, the company does not intend to further pursue development of BLU-5937 in pruritic conditions.
    • 13 Dec 2021 Results published in the BELLUS Health Media Release.
    • 13 Dec 2021 Primary endpoint (Change from baseline in weekly mean Worst Itch Numeric Rating Scale (WI-NRS) score) has not been met, according to a BELLUS Health media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top